Contingency Management for Cannabis Use for Persons With HIV

The University of Texas System (UT)

Status

Completed

Conditions

HIV Infections

Marijuana

Treatments

Behavioral: Contingency Management - Cannabis

Study type

Interventional

Funder types

Other

NIH

Identifiers

NCT04866004

HSC-MS-20-0886

K01DA047912 (U.S. NIH Grant/Contract)

HSC20220688H (Other Identifier)

Details and patient eligibility

About

The purpose of this study is to determine the feasibility and impact of 28-days of monitored abstinence from cannabis use on symptoms of depression and anxiety, pain, sleep, cannabis use withdrawal, HIV viral load and biomarkers of systemic inflammation among PLWH and who use cannabis regularly (weekly or more often). This will be a single arm pilot feasibility trial involving a contingency management program to induce cannabis abstinence. Specifically, the contingency management program will provide motivational (monetary) incentives to participants who achieve biochemically verified cannabis abstinence. Over the 28-days of this pilot feasibility trial, participants will attend seven study visits. During these visits, participants will complete survey questionnaires to assess sociodemographic, psychosocial, and behavioral factors. In addition, participants will provide blood and urine specimens for testing and quantitation of HIV viral load, biomarkers of systemic inflammation and for the detection of cannabis and other drugs of abuse.

Enrollment

25 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

HIV-positive (confirmed via HIV medication or relevant HIV labs in subject's name)
Self-report of cannabis use at least once per week in the 6-month period prior to consent
Provide a positive urine toxicology (UTOX) screen for cannabis
Not seeking treatment for cannabis use
Willing to stop using cannabis for 28 days and attend eight study visits over six weeks.
Ability and willingness to provide inform consent
English fluency

Exclusion criteria

Currently receiving treatment for cannabis or other drug use disorder
Diagnosed or receiving treatment for a current major depressive or anxiety disorder
Diagnosed with any current alcohol or substance use disorder (excluding nicotine) using the Structured Clinical Interview for Clinical Disorders (SCID) Interview (22)
Positive UTOX screen for opioids
Having a medical, psychiatric, occupational, or other condition that, in the judgment of the study physician, would make participation difficult or unsafe.